Cellectis Announces FDA Grants Orphan Drug And Rare Pediatric Disease Designation To UCART22 For Acute Lymphoblastic Leukemia Treatment; ALL Represents 10% Of U.S. Leukemia Cases And Progresses Rapidly
Portfolio Pulse from Benzinga Newsdesk
Cellectis announced that the FDA has granted Orphan Drug and Rare Pediatric Disease Designation to its UCART22 treatment for Acute Lymphoblastic Leukemia (ALL). ALL accounts for 10% of U.S. leukemia cases and progresses rapidly.
July 25, 2024 | 8:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cellectis received FDA Orphan Drug and Rare Pediatric Disease Designation for UCART22, a treatment for Acute Lymphoblastic Leukemia. This designation can provide market exclusivity and financial incentives.
The FDA's Orphan Drug and Rare Pediatric Disease Designation can significantly benefit Cellectis by providing market exclusivity, tax credits, and potential grants. This is likely to positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100